| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Regular Articles |
TAp73 Isoforms Are Frequently Up-regulated in Ovarian Cancer. Evidence for Their Role as Epigenetic p53 Inhibitors in Vivo
1 Department of Pathology, State University of New York at Stony Brook, Stony Brook, New York; 2 Abteilung für Gynäkologie und Geburtshilfe and 3 Biostatistisches Institut, Universität Innsbruck, Innsbruck, Austria; 4 Obstetrics and Gynecology, University of Vienna and Ludwig-Boltzmann-Institute for Gynecology and Gynecological Oncology, Vienna, Austria
Despite strong homology, the roles of TP53 and TP73 in tumorigenesis seem to be fundamentally different. In contrast to TP53, tumor-associated overexpression of TP73 in many different cancers, combined with virtual absence of inactivating mutations and lack of a cancer phenotype in the TP73 null mouse are inconsistent with a suppressor function but instead support an oncogenic function. The discovery of NH2-terminally truncated p73 isoforms, collectively called 
TAp73, is now the focus of intense interest because they act as potent transdominant inihibitors of wild-type p53 and transactivation-competent TAp73. Therefore, establishing deregulated TAp73 expression in tumors could be the crucial link to decipher which of the two opposing roles of this bipolar gene is the biologically relevant one. This study is the largest to date and encompasses 100 ovarian carcinomas with complete expression profile of all NH2-terminal isoforms, discriminating between TAp73 and TAp73 (Np73, N'p73, Ex2p73, and Ex2/3p73) by isoform-specific real-time reverse transcription-PCR. We find that the set of NH2-terminal p73 isoforms distinguishes ovarian cancer patients from healthy controls and thus is a molecular marker for this diagnosis. Ovarian cancers strongly and almost universally overexpress N'p73 compared with normal tissues (95% of cancers). About one-third of tumors also exhibit concomitant up-regulation of the antagonistic TAp73, whereas only a small subgroup of tumors overexpress Np73. Thus, deregulation of the E2F1-responsive P1 promoter, rather than the alternate P2 promoter, is mainly responsible for the production of transdominant p53/TAp73 antagonists in ovarian cancer. Tumor stage, grade, presence of metastases, p53 status, and residual disease after resection are significant prognostic markers for overall and recurrence-free survival. A trend is found for better overall survival in patients with low expression of N'p73/Np73, compared with patients with high expression. A strong correlation between deregulated TAp73 and p53 status exists. p53 wild-type cancers exhibit significantly higher deregulation of N'p73, Np73, and Ex2/3p73 than p53 mutant cancers. This data strongly supports the hypothesis that overexpression of transdominant p73 isoforms can function as epigenetic inhibitors of p53 in vivo, thereby alleviating selection pressure for p53 mutations in tumors.
This article has been cited by other articles:
|
|
 |
|
  W. H. Toh, E. Logette, L. Corcos, and K. Sabapathy TAp73{beta} and DNp73{beta} activate the expression of the pro-survival caspase-2S Nucleic Acids Res., August 1, 2008; 36(13): 4498 - 4509. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Muscolini, R. Cianfrocca, A. Sajeva, S. Mozzetti, G. Ferrandina, A. Costanzo, and L. Tuosto Trichostatin A up-regulates p73 and induces Bax-dependent apoptosis in cisplatin-resistant ovarian cancer cells Mol. Cancer Ther., June 1, 2008; 7(6): 1410 - 1419. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Marchini, M. Marabese, E. Marrazzo, P. Mariani, D. Cattaneo, R. Fossati, A. Compagnoni, R. Fruscio, A. A. Lissoni, and M. Broggini {Delta}Np63 expression is associated with poor survival in ovarian cancer Ann. Onc., March 1, 2008; 19(3): 501 - 507. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Malaguarnera, V. Vella, G. Pandini, M. Sanfilippo, V. Pezzino, R. Vigneri, and F. Frasca TAp73{alpha} Increases p53 Tumor Suppressor Activity in Thyroid Cancer Cells via the Inhibition of Mdm2-Mediated Degradation Mol. Cancer Res., January 1, 2008; 6(1): 64 - 77. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Tannapfel, K. John, N. Mise, A. Schmidt, S. Buhlmann, S. M. Ibrahim, and B. M. Putzer Autonomous growth and hepatocarcinogenesis in transgenic mice expressing the p53 family inhibitor DNp73 Carcinogenesis, January 1, 2008; 29(1): 211 - 218. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Dominguez and F. Bonilla In Reply J. Clin. Oncol., April 10, 2007; 25(11): 1453 - 1454. [Full Text] [PDF]
|
|
|
|
 |
|
 R Malaguarnera, V Vella, R Vigneri, and F Frasca p53 family proteins in thyroid cancer Endocr. Relat. Cancer, March 1, 2007; 14(1): 43 - 60. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. R. Watson, A. Blanch, D. C. C. Lin, M. Ohh, and M. S. Irwin Mdm2-mediated NEDD8 Modification of TAp73 Regulates Its Transactivation Function J. Biol. Chem., November 10, 2006; 281(45): 34096 - 34103. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. S. Liu, K. Y.-K. Chan, A. N.-Y. Cheung, X.-Y. Liao, T.-W. Leung, and H. Y.-S. Ngan Expression of {Delta}Np73 and TAp73{alpha} Independently Associated with Radiosensitivities and Prognoses in Cervical Squamous Cell Carcinoma. Clin. Cancer Res., July 1, 2006; 12(13): 3922 - 3927. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Dominguez, J. M. Garcia, C. Pena, J. Silva, V. Garcia, L. Martinez, C. Maximiano, M. E. Gomez, J. A. Rivera, C. Garcia-Andrade, et al. {Delta}TAp73 Upregulation Correlates With Poor Prognosis in Human Tumors: Putative In Vivo Network Involving p73 Isoforms, p53, and E2F-1 J. Clin. Oncol., February 10, 2006; 24(5): 805 - 815. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Concin, G. Hofstetter, A. Berger, A. Gehmacher, D. Reimer, R. Watrowski, D. Tong, E. Schuster, L. Hefler, K. Heim, et al. Clinical Relevance of Dominant-Negative p73 Isoforms for Responsiveness to Chemotherapy and Survival in Ovarian Cancer: Evidence for a Crucial p53-p73 Cross-talk In vivo Clin. Cancer Res., December 1, 2005; 11(23): 8372 - 8383. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Talos, O. Petrenko, P. Mena, and U. M. Moll Mitochondrially Targeted p53 Has Tumor Suppressor Activities In vivo Cancer Res., November 1, 2005; 65(21): 9971 - 9981. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. A. Johnson, E. M. Shepard, and K. W. Scotto Differential Regulation of MDR1 Transcription by the p53 Family Members: ROLE OF THE DNA BINDING DOMAIN J. Biol. Chem., April 8, 2005; 280(14): 13213 - 13219. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Tomkova, A. Belkhiri, W. El-Rifai, and A. I. Zaika p73 Isoforms Can Induce T-Cell Factor-Dependent Transcription in Gastrointestinal Cells Cancer Res., September 15, 2004; 64(18): 6390 - 6393. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
